Fig. 3: Synaptic biomarkers explain a greater proportion of variance in CSF t-tau than neurodegeneration biomarkers. | Nature Communications

Fig. 3: Synaptic biomarkers explain a greater proportion of variance in CSF t-tau than neurodegeneration biomarkers.

From: CSF total tau as a proxy of synaptic degeneration

Fig. 3

Bar charts show mean (±s.d.) the partial R² in (left) cognitively unimpaired (n = 188) and (right) cognitively unimpaired groups (n = 84). Partial R² values were estimated only for individuals who had complete data for all the following biomarkers: CSF t-tau as the outcome and biomarkers reflecting neurodegeneration (HCV and CSF NfL) and synaptic degeneration (CSF Ng and SNAP25) as predictors in linear regression models. Models were adjusted for age, sex, and cohort, and compared using AIC. Bootstrapping (n = 1000 iterations) was applied to assess the stability of the partial R² values. *indicate Akaike Information Criterion difference (ΔAIC) between neurodegeneration and synaptic degeneration >15. Cognitively unimpaired ΔAIC = 339; cognitively impaired ΔAIC = 95. Cerebrospinal fluid (CSF). Total-tau (t-tau). Hippocampal volume (HCV). Neurofilament light chain protein (NfL). Neurogranin (Ng). Synaptosomal-associated protein 25 (SNAP25). Standard deviation (s.d.). Source data are provided as a Source Data file.

Back to article page